Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Imbruvica - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Imbruvica

Approved

STANDARD

Imbruvica

Cilag AG🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 3df1ba41570fc15b
Company: Cilag AG
Type: Standard

Approval Details

Approval Id: 3df1ba41570fc15b
Drug Approval Philippines Name: Imbruvica
Product Name: Imbruvica
Registration Number: DR-XY48674
Brand Name: Imbruvica
Generic Name: Ibrutinib
Dosage Form: Film-Coated Tablet
Dosage Strength: 420 mg
Manufacturer: Cilag AG
Importer: Johnson & Johnson (Philippines), Inc.
Company Detail Path: /organization/cilag-ag
Issuance Date: 28 September 2023
Expiry Date: 30 March 2028
Pharmacologic Category: Antineoplastic Agent (Protein Kinase Inhibitor)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

3df1ba41570fc15b

Type

Standard

Back to Philippines FDA Approvals